Abeona Therapeutics (ABEO)

Abeona Therapeutics (ABEO) Income Statement


Abeona Therapeutics Income Statement

Last quarter (Q1 2024), Abeona Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q1, Abeona Therapeutics's net income was $-31.58M. See Abeona Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 3.50M$ 3.50M$ 1.41M$ 3.02M$ 10.00M$ 0.00
Cost of Revenue
-$ 1.60M----
Gross Profit
$ 3.50M$ 1.90M$ 1.41M$ 3.02M--
Operating Expense
$ 24.27M$ 50.09M$ 52.33M$ 60.37M$ 58.50M$ 77.09M
Operating Income
$ -51.56M$ -47.13M$ -50.91M$ -57.35M$ -48.50M$ -77.09M
Net Non Operating Interest Income Expense
$ -1.27M$ -1.70M$ -736.00K$ -3.66M$ -2.81M$ 808.00K
Other Income Expense
$ 28.16M$ -7.69M$ -7.52M$ -9.00K$ -32.92M-
Pretax Income
$ -50.13M$ -54.19M$ -36.11M$ -93.47M$ -84.23M$ -76.28M
Tax Provision
$ -11.38M$ -11.38M----
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -76.67M$ -54.19M$ -43.48M$ -85.01M$ -84.23M$ -76.28M
Basic EPS
$ -1.36$ -2.53$ -5.53-$ -0.91$ -1.51
Diluted EPS
$ -1.36$ -2.53$ -5.53$ -21.50$ -0.91$ -1.51
Basic Average Shares
$ 95.93M$ 21.38M$ 7.86M$ 3.94M$ 92.66M$ 50.35M
Diluted Average Shares
$ 95.93M$ 21.38M$ 7.86M$ 3.94M$ 92.66M$ 50.35M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 24.27M$ 51.70M$ 48.01M$ 60.37M$ 58.50M$ 77.09M
Net Income From Continuing And Discontinued Operation
$ -76.66M$ -54.19M$ -39.70M$ -85.01M$ -84.23M$ -76.28M
Normalized Income
$ -56.07M$ -68.72M--$ -51.32M$ -76.28M
Interest Expense
----$ 4.12M$ 400.00K
$ -48.86M$ -53.77M$ -38.96M$ -89.81M$ -80.12M$ -75.88M
$ -45.86M$ -50.57M$ -34.76M$ -85.23M$ -74.52M$ -67.20M
Currency in USD

Abeona Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis